Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2004-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of the study was to determine the efficacy of CDP870 in treating RA signs/symptoms in patients who were partial responders to MTX. Other purposes were to show additional efficacy without increased toxicity and the immunogenic response to CDP870 during combined CDP870 and MTX therapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UCB Pharma
• Treatments: Certolizumab Pegol; Methotrexate

Criteria

Inclusion Criteria:

• male/female, 18-75 years old, inclusive

• diagnosis of adult-onset RA

• had active disease

• had received methotrexate

• on a stable dose of folic acid

Exclusion Criteria:

• contraindication for methotrexate or anti-TNF